IBRX Latest Headlines

ImmunityBio sets November 2026 topline timeline after database lock in 366-patient ANKTIVA plus BCG bladder-cancer trial

Market Chameleon (Wed, 21-Oct 8:14 AM)

ImmunityBio Highlights 84% Cystectomy Avoidance at Three Years in Long-Term ANKTIVA Plus BCG Follow-Up

Market Chameleon (Mon, 19-Oct 11:38 AM)

IBRX gains broader access for ANKTIVA as FDA label expands to papillary-only NMIBC, a group representing about 85% of patients

Market Chameleon (Thu, 15-Oct 7:09 AM)

ImmunityBio Taps Founder Patrick Soon-Shiong for an Oct. 16 Piper Sandler Oncology Fireside Chat

Market Chameleon (Fri, 9-Oct 11:37 AM)

ImmunityBio (IBRX) highlights ANKTIVA progress ahead of an Oct. 16 Piper Sandler fireside chat

Market Chameleon (Thu, 8-Oct 8:46 AM)

IBRX’s eight straight quarters of ANKTIVA revenue growth puts commercial execution at center stage

Market Chameleon (Mon, 5-Oct 7:31 AM)

IBRX Rises as Director Linda Maxwell Adds Another Board Seat After HLS Appointment

Market Chameleon (Fri, 2-Oct 11:36 AM)

ImmunityBio’s Revenue Jump and Global Expansion Highlight a Turning Point Despite Steep Losses

Market Chameleon (Tue, 4-Aug 7:42 AM)

UAE Leads with World’s Broadest ANKTIVA Approval: ImmunityBio Gains Crucial Bladder and Lung Cancer Clearances

Market Chameleon (Thu, 30-Jul 7:08 AM)